Avastin (bevacizumab) - 400mg - For Intravenous Use

Description (Brief)
(From box) For Intravenous Use
(From insert)
Metastatic Colorectal Cancer (mCRC) Avasitin is indicated for the first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum in combination with intravenous 5-flurouracil-based chemotherapy.
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Avastin is indicated for the first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel.
Glioblastoma Avastin is indicated for the treatment of glioblastoma with progressive disease in adult patients following prior therapy as a single agent. The effectiveness of Avastin in glioblastoma is based on an imporvement in objective response rate. There are no data demonstrating an improvement in disease-related symptoms or increased survivial with Avastin.
Metastatic Renal Cell Carcinoma (mRCC) Avastin is indicated for the treatment of metastatic renal cell carcinoma in combination with interferon alfa.
Location
Currently not on view
date made
ca 2013
product expiration date
2014-10
maker
Genentech, Inc.
place made
United States: California, South San Francisco
Physical Description
metal (overall material)
plastic (overall material)
glass (overall material)
cardboard (overall material)
bevacizumab, 400 mg (20mg/mL) (overall ingredient)
Measurements
overall: 1 1/2 in x 2 3/4 in x 5 1/4 in; 3.81 cm x 6.985 cm x 13.335 cm
avastin bottle: 2 1/2 in x 1 1/4 in; 6.35 cm x 3.175 cm
overall: 5 1/4 in x 2 3/4 in x 1 1/2 in; 13.335 cm x 6.985 cm x 3.81 cm
ID Number
2013.0069.02
catalog number
2013.0069.02
accession number
2013.0069
maker number
510569
Credit Line
Gift of Genentech, Inc.
See more items in
Medicine and Science: Medicine
Health & Medicine
The Antibody Initiative
Antibody Initiative: Monoclonal Antibodies
Data Source
National Museum of American History